Sussex Research Laboratories Inc. Laboratories Inc., the leading specialist in carbohydrate synthesis, glycosylation and glycodesign, is pleased to announce that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/103,452 entitled “GLYCOPEPTIDE COMPOSITIONS AND USES THEREOF.” The patent covers the Company’s novel cosmetic active ingredient, GlycolastinTM, a glycosylated peptide developed as an anti-wrinkling cosmetic active that efficiently improves the appearance of fine lines and wrinkles while also increasing skin hydration and elasticity. In vitro studies have shown that GlycolastinTM stimulates at least 3 major constituents of skin that are all important for the maintenance of healthy skin. In vivo studies demonstrated that, within 42 days, crow’s feet wrinkles were visibly decreased while also improving skin hydration and elasticity.
Dr. Brady Clark, President and Chief Executive Officer stated: “This is the first of what we hope will be several patents that we expect to receive to protect our GlycolastinTM technology which utilizes glycosylation to improve the effectiveness of cosmetic peptide actives. We expect finished products that utilize this unique active to be introduced in 2018.”
Glycolastin™has been developed by Sussex Research Laboratories Inc. to exploit the field of glycobiology in order to advance a new and state-of-the-art anti-aging technology. In vitro studies have shown that Glycolastin™ is significantly more efficient at stimulating structural protein synthesis in skin cells than the non-glycosylated peptide active, a well-known peptide active in the cosmetics field. Increased secretion of structural proteins elastin, fibronectin and collagens by fibroblasts was observed in vitro for glycosylated peptides compared to the non-glycosylated reference peptide. The in vitro effect on elastin secretion has also been confirmed independently in a 3D ex vivo skin model. Patents have been filled in numerous jurisdictions.
About Sussex Research Laboratories Inc.:
Sussex Research Laboratories Inc. is a contract research organization and leading specialist in the design, synthesis and characterization of carbohydrate-based systems and stable isotope-labeled molecules. We excel at synthesis of molecules that incorporate elements of carbohydrates, glycans and polysaccharides. Our product portfolio and contract synthesis services enable our clients and partners to explore and exploit glycosylation or stable isotope-labeling for drug discovery, drug delivery, carbohydrate-based vaccine development, therapeutic enhancement and bio-analytical assay development. For more information visit www.sussex-research.com.
SHARE THIS ARTICLE ON:
Get product updates and announcements from Sussex Research in your inbox at no charge.
Sussex Research Laboratories Inc. to Exhibit at TIDES USA 2022: Oligonucleotide & Peptide Therapeutics
May 4, 2022
Sussex Research Laboratories Inc. to Exhibit at The American Peptide Symposium 2022 - "Peptide Science at the Summit"
April 26, 2022
Sussex Research Laboratories Inc. / Queen’s University collaboration receives support to develop novel small molecule therapies for COVID-19
May 21, 2020
Sussex Research Laboratories Inc. / Queen’s University collaboration receives Collaborative Research and Development Grant (CRDPJ) to develop synthetic strategies toward Deuterium-labeled pharmaceutical compounds with improved efficacy.
August 22, 2018
Sussex Research Laboratories Inc. acquires Chemaphor Chemical Services from Avivagen
October 13, 2017